Results from the WATCH AF and DETECT AF PRO trials
Jens ECKSTEIN (Basel, Switzerland)
Major findings will be introduced:
international, multicentre, double-blind clinical trial, tested the accuracy of Preventicus Nightwatch® in analysing 1-minute plethysmographic raw data, captured via the Samsung Gear Fit II in 636 study participants.
It is the world’s first international, prospective, double-blinded and multicenter clinical trial (ClinicalTrials.gov ID: NCT02956343) evaluating the accuracy of a smartwatch to detect atrial fibrillation. Preventicus provided the application for blinded analysis of 1 minute plethysmographic raw data (recorded with pulse sensor of Samsung Gear Fit II smartwatch) of 636 study participants. Major findings: Total accuracy of the application was 95.7% with a positive predictive value of 97.8% in comparison to the ECG based diagnosis of two cardiologists by mutual agreement.